Skip Navigation

European Heart Journal 1987 8(2):148-153;
Copyright © 1987 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by LEWIS, R.
Right arrow Articles by MCDEVITT, D. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by LEWIS, R.
Right arrow Articles by MCDEVITT, D. G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1987 The European Society of Cardiology

A comparison of verapamil and digoxin in the treatment of atrial fibrillation

R. LEWIS, M. LAKHANI, T. A. MORELAND* and D. G. MCDEVITT

Department of Pharmacology and Clinical Pharmacology, Ninewells Hospital and Medical School Dundee DD1 9SY, U.K.
*Department of Drug Development (Scotland) Ltd, Ninewells Hospital and Medical School Dundee DD1 9SY, U.K.

Received 28 May 1986; revised 9 July 1986; .

Abstract

Twelve patients (including 2 females) with chronic atrial fibrillation were entered into a randomized, double blind crossover study to compare the effects of digoxin and verapamil upon heart rate, exercise tolerance and symptom control. The dose of digoxin was adjusted so as to give serum concentrations within the range 1.3 to 2.6 nmol l–1 between four and six hours after dosing, and was continued for six weeks. The dose of verapamil was increased from 40 mg tds to 80 mg tds to 120 mg tds at fortnightly intervals. Three patients did not complete the study; two because of adverse effects attributable to verapamil. In the remaining nine patients, mean post exercise heart rates were significantly lower during treatment with verapamil 80 mgs tds (126.7bpm) than with verapamil 40 mg tds (148.6 bpm) or digoxin (146.7 bpm). However, exercise tolerance was similar with both verapamil and digoxin and the superior control of exercise induced tachycardia achieved with higher doses of verapamil was not associated with improved exercise endurance. Visual analogue scale scores for constipation were significantly higher during treatment with verapamil; scores for other possible side effects and for overall wellbeing were similar. The results do not confirm the findings of others who have reported that verapamil is superior to digoxin in the treatment of atrial fibrillation.

Key Words: Verapamil • digoxin • atrial fibrillation


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 BMJHome page
T. Nikolaidou and K. S Channer
Rate control in permanent atrial fibrillation
BMJ, November 24, 2007; 335(7629): 1057 - 1058.
[Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
B. Olshansky, L. E. Rosenfeld, A. L. Warner, A. J. Solomon, G. O'Neill, A. Sharma, E. Platia, G. K. Feld, T. Akiyama, M. A. Brodsky, et al.
The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: Approaches to control rate in atrial fibrillation
J. Am. Coll. Cardiol., April 7, 2004; 43(7): 1201 - 1208.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.